Q1 2025 Management View Liz Barrett, President and Chief Executive Officer, highlighted that "the new drug application for ...

Trump's executive order sets a deadline for drugmakers to lower the cost of prescription drugs in the U.S. or face new limits ...

The Food and Drug Administration (FDA) recently announced that it had identified “significant data integrity and study conduct concerns” ...

The majority of RNAs in each of our cells don't code for any of the thousands of proteins that make up our bodies. Instead, ...

Ireland’s Health and Safety Executive has criticised a new report revealing the country’s shocking last place in Western Europe for new oncology drug access.

The FDA has cleared investigational new drug applications and handed out fast track designations. Plus, data shows promise for novel therapies in hard-to-treat cancers.

The FDA cleared the investigational new drug application of IDE849, a potential first-in-class DLL3-targeted antibody-drug ...

We recently compiled a list of the 11 Stocks That Will Bounce Back According To Analysts. In this article, we are going to ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for milsaperidone (Bysanti™) for the treatment of acute ...

Delaying Medicare’s ability to negotiate prices on small-molecule drugs until 13 years after FDA approval will decrease the ...

Viatris shares favorable Phase 3 data for contraceptive patch and pain drug, affirms 2025 sales, and raises adjusted EPS ...

The investigational transdermal delivery system, known as Xulane Lo, is designed to deliver 150mcg of norelgestromin and 17.5mcg of ethinyl estradiol per day.